Literature DB >> 29062232

Mitochondrial multiorgan disorder syndrome score generated from definite mitochondrial disorders.

Josef Finsterer1, Sinda Zarrouk-Mahjoub2.   

Abstract

OBJECTIVES: Mitochondrial disorders (MIDs) frequently present as mitochondrial multiorgan disorder syndrome (MIMODS) at onset or evolve into MIMODS during the course. This study aimed to find which organs and/or tissues are most frequently affected by MIMODS, which are the most frequent abnormalities within an affected organ, whether there are typical MIMODS patterns, and to generate an MIMODS score to assess the diagnostic probability for an MID.
METHODS: This is a retrospective evaluation of clinical, biochemical, and genetic investigations of adult patients with definite MIDs. A total of 36 definite MID patients, 19 men and 17 women, aged 29-82 years were included in this study. The diagnosis was based on genetic testing (n=21), on biochemical investigations (n=17), or on both (n=2).
RESULTS: The number of organs most frequently affected was 4 ranging from 1 to 9. MIMODS was diagnosed in 97% of patients. The organs most frequently affected were the muscle (97%), central nervous system (CNS; 72%), endocrine glands (69%), heart (58%), intestines (55%), and peripheral nerves (50%). The most frequent CNS abnormalities were leukoencephalopathy, prolonged visually evoked potentials, and atrophy. The most frequent endocrine abnormalities included thyroid dysfunction, short stature, and diabetes. The most frequent cardiac abnormalities included arrhythmias, systolic dysfunction, and hypertrophic cardiomyopathy. The most frequent MIMODS patterns were encephalomyopathy, encephalo-myo-endocrinopathy, and encepalo-myo-endocrino-cardiopathy. The mean ± 2SD MIMODS score was 35.97±27.6 (range =11-71). An MIMODS score >10 was regarded as indicative of an MID.
CONCLUSION: Adult MIDs manifest as MIMODS in the vast majority of the cases. The organs most frequently affected in MIMODS are muscles, CNS, endocrine glands, and heart. An MIMODS score >10 suggests an MID.

Entities:  

Keywords:  cardiomyopathy; encephalomyopathy; mitochondrial cytopathy; mitochondriopathy; multiorgan; multisystem disease

Year:  2017        PMID: 29062232      PMCID: PMC5638572          DOI: 10.2147/NDT.S149067

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Mitochondrial disorders (MIDs) frequently present as multiorgan disorder syndrome (MODS) already at the onset of the disease or evolve into a mitochondrial multiorgan disorder syndrome (MIMODS) during the disease course.1,2 The term “multi-organ disorder syndrome” should not be mixed up with multiorgan dysfunction syndrome, which is used for acute multiorgan failure during severe system disease (eg, cardiogenic shock).3 MODS may occur not only in MIDs but also in disorders other than MIDs, such as myotonic dystrophy, Fabry disease, and glycogen storage disease. In general, all tissues may be affected in an MID, but those with the highest demand of oxygen or with the highest energy requirements are most frequently involved. These organs include the skeletal muscle, the peripheral nerves, the central nervous system (CNS), endocrine organs, the eyes, the ears, the heart, the arteries, the gastrointestinal tract, the kidneys, the bone marrow, the cartilage,4,5 and the skin.1 This retrospective study was carried out to assess which organs/tissues are the most frequently affected in MIMODS, which are the most frequent manifestations within an organ, and whether there are typical patterns of organ involvement suggesting an MID and to generate a score, for estimating the probability of a phenotype to represent an MID.

Methods

All patients with a definite MID diagnosed between 1992 and 2014 were retrospectively investigated. A “definite MID” was diagnosed if biochemical investigations (the determination of the respiratory chain complex activity in the muscle homogenate) revealed a single or multiple respiratory chain complex defect(s) or if a mutation causative for the phenotype could be identified (by Southern analysis, PCR, restriction fragment length polymorphism, polyacrylamide gel electrophoresis, or long PCR in lymphocytes or muscle). From each of the included patients, all available records were assessed for diseases in any of the frequently affected organs in MIDs. As a generally accepted definition of MIMODS is not available, MIMODS was diagnosed in case more than one tissue was affected. All previous and current information about history, clinical examination, and instrumental investigations available was relevant for assessing how many organs were affected in a patient. Within an organ, it was counted how many abnormalities per organ were present. Patients who are currently alive as well as those already deceased were considered. Patients with equivocal results on biochemical investigations or in case of uncertainty about the pathogenicity of a mutation such as mtDNA polymorphisms were excluded. Also patients with a probable and possible MID were excluded. Probable MIDs were defined as those without a biochemical or genetic abnormality but with abnormal histochemical findings on muscle biopsy (cytochrome oxidase–negative fibers, ragged red fibers, nicotinamide adenine dinucleotide–negative fibers, and succinate dehydrogenase hyperreactive fibers), increased lipid droplets or glycogen storage, abnormally shaped or structured mitochondria, paracrystalline inclusions, abnormal cycle lactate stress test, elevated resting lactate, or the presence of a lactate peak on cerebral magnetic resonance spectroscopy (MRS). Although MID patients frequently present with dyslipidemia or hyperuricemia, they were not regarded as MID manifestations because of the potential nutritional influence. Hyperhidrosis was regarded as a manifestation of the autonomic nervous system (ANS), since this etiology is the most frequent among MIDs, but hyperhidrosis may be due to other causes as well. Abnormal visually evoked potentials (VEPs) were regarded as indicative of a CNS lesion after the exclusion of ophthalmologic abnormalities. Although arterial hypertension can be frequently found in MIDs, it was not assessed as a manifestation of an MID since arterial hypertension is frequently multicausal. Atherosclerosis was regarded as MID manifestation only if classical cardiovascular risk factors (ie, diabetes, arterial hypertension, hyperlipidemia, and smoking) were absent. Dysphagia was regarded as a gastrointestinal MID manifestation only if there were no depression and no cerebral abnormality. The present study did not assess differences of organ involvement between the onset of the MID and the last follow-up, and it was conducted in accordance with the Declaration of Helsinki. Verbal informed consent was obtained from all included patients. The research was approved by the local institutional review board of the NKH Rosenhügel.

Results

In total, 36 adult, Caucasian patients with a definite MID, 19 men and 17 women, aged 29–82 years, were included (Table 1). Meanwhile, 7 patients had died. In 21 of the included patients, the diagnosis was based on genetic testing, in 17 patients on biochemical investigations of the muscle homogenate, and in 2 patients on both (Table 1). Three patients carried a single mtDNA deletion, 15 patients carried a single mtDNA point mutation, and 2 patients carried a point mutation in more than one mtDNA gene. In a single patient, a depletion syndrome was diagnosed. Among those with a biochemical defect, 9 patients had a single complex defect and 8 had combined complex defects (Table 1). The most frequent single-complex defect concerned C1 (n=6) followed by C4 (n=3). The most frequent combined complex defect concerned C1-4 (n=4). In 2 patients, biochemical investigations and genetic investigations had been carried out.
Table 1

Characterization of the 36 adult MID patients included in this study

PatientsAge (years)SexBCDMutationNAONAAONOIPHMIMODSs
157MndtRNA(Leu)7132343
266MnND17162649
365FC1,2,3nd6142545
479MC1-4nd7142041
581FC4nd34815
671MndtRNA(Thr)361221
746MC1-4nd5112339
851MC4nd4101529
934FC1-4nd8122040
1081FC2,3nd5122441
1170FnmtDNAdel8142345
1238FndtRNA(Glu)481325
1375FC1ND17193359
1466Fnd16S-rRNA371727
1574MC1nd5111531
1629FndmtDNAdel9204453
1759MC1nd461222
1856MndND14122339
1943Mndcytb, ND19214171
2064MndtRNA(Lys)6102238
2145FndmtDNAdel451019
2282FC1nd7162952
2373FndtRNA(Lys)7153254
2462MC2,3nd6111431
2547MndND3381122
2650MC4nd7102138
2782Fndcytb5101732
2868FndtRNA(Lys)4111933
2944MndtRNA(Lys)1113
3060MndND323611
3165FndtRNA(Iso), cytb, ATP68183157
3268MC1nd461424
3353MndND1471526
3449FC1-4mtDNA depletion471021
3567FC1nd7101835
3667MC2,3,4nd5112137

Note: Gene names are in italics.

Abbreviations: BCD, biochemical defect; C, respiratory chain complex; F, female; M, male; MID, mitochondrial disorder; MIMODSs, mitochondrial multiorgan disorder syndrome score; n, normal; NAAO, number of abnormalities in all organs; NAO, number of affected organs; nd, not done; NOIPH, number of individual PubMed hits.

In one patient, only a single organ (muscle) was affected at the time of the last available investigation. In one patient, 2 organs were affected, in 4 patients 3 organs, in 10 patients 4 organs, in 4 patients 5 organs, in 3 patients 6 organs, in 8 patients 7 organs, in 3 patients 8 organs, and in 2 patients 9 organs (Figure 1). None of the patients had involvement of >9 organs. The number of organs most frequently affected in MIMODS was 4. In total, 35 patients with MIMODS (97%) were identified. The organs most frequently affected in patients with MIMODS were the skeletal muscle (n=35), the CNS (n=27), the endocrine glands (n=26), the heart (n=21), the intestines (n=20), and the peripheral nerves (n=19; Table 2). The ears (n=11), the bone marrow (n=11), the eyes (n=8), the kidneys (n=7), the skin (n=6), and the bones (n=4) were rarely affected organs. The only organ not affected in this cohort was the vasculature and the lungs. MIMODS was as frequent in women as in men (Figure 1).
Figure 1

Frequency of organ involvement and gender difference among 36 patients with definite MID.

Abbreviations: MID, mitochondrial disorder; NOP, number of patients.

Table 2

Abnormalities (n=63) in organs frequently affected by an MID in the present investigation and the literature

OrganLiterature reported abnormalitiesNOPWTAPubMed hitsPubMed pointsReferences
MuscleProgressive external ophthalmoplegia6~500333
Ptosis9~150334
Easy fatigability, exercise intolerance13~110335
Limb weakness20~60236
Hyper-CK-emia20~55237
Wasting19~50131
Respiratory insufficiency1~45136
Myoglobinuria1~30135
Cramping918138
Myalgia1416135
Abnormal lactate stress test1515139
Double vision, diplopia811140
Stiffness25141
Fasciculations53138
Muscle rupture21142
CNSEpilepsy4~600343, 44
Cortical, subcortical, cerebellar, BS atrophy7~250345
Ataxia4~200346
Parkinson0~150347
Dementia2~100348
Stroke-like episodes0~50245
Migraine2~50231
Dystonia0~40149
Tremor6~40147
Leucencephalopathy, white matter lesions12~35150
Spasticity5~25146
Dysarthria2~20151
Psychosis0~15152
Confusional state0~15153
Mild cognitive impairment4~10154
Basal ganglia calcification110145
Dilative arteriopathy01155
Delayed visually evoked potentials71156
Myelopathy01157, 58
EndocrineDiabetes9~700337
Short stature12~80220
Thyroid dysfunction20~20159
Hypoparathyroidism2~15160
Adrenal insufficiency (Addison’s disease)0~15161
Hypogonadism5~15146
Osteoporosis7~10162
Pituitary adenoma04163
Ovarian cysts12164
Gynecomastia12165
HeartHypertrophic, dilated, restrictive CMP7~250366
Heart failure, systolic dysfunction8~70267
Arrhythmias14~60268
Arterial hypertension0~50169
Noncompaction4~15170
Pulmonary hypertension0~10171
Aortic root ectasia010125
Coronary heart disease03172, 73
Congenital heart disease02132
GIHepatopathy9~100374
Vomiting1~20175
Diarrhea5~20175
Pancreatitis2~20176
Steatosis hepatis3~15177
Nonspecific colitis1~10178
Diverticulosis31179
Sialadenitis01113
PNNeuropathy18.100380
Neuronopathy12154, 81

Abbreviations: BS, brain stem; CK, creatine kinase; CMP, cardiomyopathy; CNS, central nervous system; GI, gastrointestinal; MID, mitochondrial disorder; NOPWTA, number of patients with this abnormality; PN, peripheral nerve.

Among the 35 patients with myopathy, 20 patients had weakness of the limb muscles, 19 had muscle wasting, 14 had myalgias, 13 had exercise intolerance, 10 had muscle cramps, 9 had ptosis, 8 had double vision, 6 had chronic progressive external ophthalmoplegia (CPEO), 6 had sore muscles, 5 had fasciculations, 2 had muscle stiffness, and 2 patients had a history of a muscle rupture. In one patient, respiratory muscles were involved. In 34 patients, creatine kinase (CK) was determined and elevated in 20 patients. In a single patient, myoglobinuria was detected. The lactate stress test on a cycle ergometer was carried out in 26 patients and was abnormal (indicative of an MID) in 15 patients. The electromyography (EMG) was carried out in 35 patients and myogenic in 13, neurogenic in 7, and normal in 15 patients. Among the 27 patients with CNS involvement, 12 had leukoencephalopathy, 7 had abnormal VEPs, 7 had focal or diffuse atrophy, 6 had tremor, 6 had cognitive impairment, 5 had spasticity, 4 had epilepsy, 4 had ataxia or dysmetria, 2 had migraine, 2 had dysarthria, 1 had basal ganglia calcification, 1 had an arachnoid cyst, and 1 had restless leg syndrome (RLS; Table 2). None of the patients underwent MRS or reported a stroke-like episode. Among the 26 patients with endocrine abnormalities, 20 had thyroid dysfunction, 12 had short stature, 9 had diabetes, 7 had osteoporosis, 5 had hypogonadism, 2 had parathyroid dysfunction, 2 had prostate hypertrophy, and 1 each had ovarian cysts, endometriosis, and gynecomastia, respectively. Among the 21 patients with cardiac involvement, 14 had arrhythmias, 8 had systolic dysfunction or heart failure, 5 had hypertrophic cardiomyopathy, 2 had dilative cardiomyopathy, 4 had valve abnormalities, 4 had noncompaction (left ventricular hypertrabeculation [LVHT]), and 1 each had pericarditis and abnormal myocardial texture, respectively (Table 2). Five were supplied with a pacemaker, but none with an implantable cardioverter defibrillator. Among the 20 patients with gastrointestinal abnormalities, 9 had hepatopathy with only elevated liver enzymes, 5 had diarrhea, 3 had diverticulosis, 3 had steatosis hepatis, 2 had pancreatitis, and 1 each had hyperemesis, hepatomegaly, nonspecific colitis, and liver cysts, respectively (Table 2). Among the 19 patients with peripheral nervous system involvement (ie, myopathy, neuropathy, or neuronopathy), 18 had neuropathy with motor, sensory, or ANS involvement and 1 had neuronopathy. The ANS was affected in 4 patients manifesting as hyperhidrosis. Among the 11 patients with otologic involvement, 11 had hypoacusis or anacusis and 4 had tinnitus. Among the 10 patients with hematological abnormalities, 10 had anemia, 2 had thrombocytopenia, and 1 had leucopenia. Affection of the bones/cartilage resulted in polyarthralgia (n=2), arthrosis (n=2), facial dysmorphism (n=1), and hypertelorism (n=1). Among the 9 patients with ophthalmologic involvement, 2 had cataract, 3 had glaucoma, 2 had pigmentary retinopathy, and 2 had optic atrophy. Among the 7 patients with renal involvement, 5 had renal insufficiency, 2 had nephrolithiasis, and 1 had renal cysts. Seven patients had dermal involvement manifesting as lipomatosis (n=2), psoriasis (n=1), basal cell carcinoma (n=1), seborrheic eczema (n=1), and atopic dermatitis (n=1). The number of abnormalities in all the affected organs per patient ranged from 1 to 21. Myopathy manifested with 15 of 15 different abnormalities, CNS involvement with 11 of 18 abnormalities, endocrine involvement with 7 of 10 abnormalities, cardiac involvement with 4 of 9 abnormalities, gastrointestinal involvement with 7 of 8 abnormalities, ophthalmologic involvement with 4 of 4 abnormalities, otologic involvement with 2 of 2 abnormalities, renal involvement with 3 of 4 abnormalities, hematologic involvement with 3 of 3 abnormalities, bone/cartilage involvement with 4 of 4, and dermal involvement with 4 of 10 abnormalities. In none of the patients could mitochondrial vasculopathy be unequivocally attributed to MID. Among the 10 patients with a neoplasm (28%), 6 had developed a benign neoplasm and 4 had a malignant neoplasm. No typical pattern of organ involvement could be extracted from this study, but most of the patients presented with myopathy, CNS disease, endocrine abnormalities, and cardiac dysfunction. As 35 patients had myopathy and 27 patients had CNS involvement, encephalo-myopathy was the most frequent pattern of organ involvement. However, more frequently than 2 organs, 3 or 4 organs were simultaneously involved resulting encephalo-myo-endocrinopathy or encephalo-myo-endocrino-cardiomyopathy. The MIMODS score was calculated as the sum of 3 figures: 1) the number of organs affected (maximal number =13); 2) the number of abnormalities within an organ (maximal number =94 [2–18 per organ]) (Table 2); and 3) the number of hits a PubMed search for each single-organ involvement by means of the search terms “specific abnormality,” “mitochondrial,” “human,” and “mutation” generated. If the number of hits exceeded 100, 3 points were additionally assigned for an abnormality, 2 points in case of 51–100 hits, and 1 point in case of 1–50 hits. The mean ± SD of the MIMODS score calculated from 35 patients (one patient did not have MIMODS) was 35.97±27.6 ranging from 11 to 71. An MIMODS score >10 was thus regarded as indicative of an MID. If MIMODS was defined as >2 organ involvement, a score >14 was indicative of MID.

Discussion

This study shows that MIMODS is frequent among non-selected patients with a definite MID. The most frequently involved organs in MIMODS are the muscle, CNS, endocrine glands, heart, and the gastrointestinal tract. Limb weakness, encephalopathy, thyroid dysfunction, and arrhythmias were the most frequent abnormalities of myopathic, CNS, endocrine, and cardiac involvement. The most frequent pattern of organ involvement in MIMODS was encephalo-myopathy, encephalo-myo-endocrinopathy, and encephalo-myo-endocrino-cardiomyopathy. An MIMODS score >10 suggests an MID. The multiorgan nature of most MIDs is well established in the literature and supported by several studies (Tables 2 and 3).6 Whether MIMODS is more frequent in specific MIDs than in nonspecific MIDs is unknown. Among the specific MIDs, MIMODS has been particularly reported in Pearson syndrome,7–10 Kearns–Sayre syndrome (KSS), CPEO, sensory ataxic neuropathy with dysarthria and ophthalmoparesis, and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS).11–14 However, MIMODS is also a frequent manifestation of nonspecific MIDs.15–21 The number of organs affected in MIMODS is assumed to depend on the disease duration, as MIDs are progressive disorders in the majority of cases with deterioration and affection of an increasing number of organs over time. Nearly all patients with single-organ involvement at the onset of the disease develop MIMODS over years. Often, this may occur not earlier than after several years of clinical stability.
Table 3

Abnormalities (n=31) in organs more rarely affected by an MID in the present investigation and the literature

OrganLiterature reported abnormalitiesNOPWTAPubMed hitsPubMed pointsReferences
EyesOptic atrophy2~400382
Retinopathy2~150383
Cataract2~40119
Glaucoma3~20184
EarsHypoacusis, anacusis11~500319
Tinnitus4~5185
KidneysRenal insufficiency, renal failure5~80286
Renal tubular acidosis046224
Fanconi syndrome0~15187
Renal cysts1~5188
Nephrolithiasis21189
VascularDissection, spontaneous rupture02126, 27
Aneurysm formation01129
Ectasia, dilative arteriopathy01155
Atherosclerosis01173, 90
BMAnemia10~80291
Thrombocytopenia2~5192
Leukopenia1~5192
BonesSkeletal abnormalitiesa2~15113, 24, 93
Polyarthralgia2114, 94
Arthrosis21195
DermisPsoriasis11196
Lipomatosis2~10131
Vitiligo02197, 98
Edema02113
Hypertrichosis02197, 98
Baldness, alopecia01199
Madarosis011100
Skin rashes01197
Seborrheic enzema11197
Atopic dermatitis11197

Note:

These include facial dysmorphism, hypertelorism, and brachydactyly.

Abbreviations: BM, bone marrow; MID, mitochondrial disorder; NOPWTA, number of patients with this abnormality.

According to the literature, any organ may be affected in an MID.6 However, the most frequently affected organs are the muscle, the CNS, endocrine glands, and the heart, which is in line with the findings of the present study.6 Frequently affected are also the eyes and ears, which was not confirmed by the presently investigated cohort. This is most likely due to the development of ophthalmologic and otologic abnormalities only later in the disease course. More rarely involved are arteries, intestines, kidneys, the hematological system, lungs, bones, cartilage, and skin. Tables 2 and 3 list the organ abnormalities described in MIDs. Among the various abnormalities found in organs of MID patients, some are more frequent than others (Tables 2 and 3). In MID patients with myopathy, the most frequently described abnormalities include CPEO, ptosis, and exercise intolerance (>100 citations). More rarely described are limb weakness, muscle wasting, and hyper-CK-emia (51–100 citations; Table 2). Among CNS abnormalities, the most frequent are epilepsy, cerebral atrophy, ataxia, Parkinson syndrome, and dementia (>100 citations). Stroke-like episodes and migraine occur more rarely (51–100 citations). Among the abnormalities of the endocrine glands, the most frequent is by far diabetes (>100 citations). The second most frequent is short stature (51–100 citations; Table 2). Among the cardiac abnormalities, the most frequent is cardiomyopathy (>100 citations). Heart failure/systolic dysfunction, arrhythmias, and arterial hypertension occur more rarely (51–100 citations). Among the gastrointestinal abnormalities, the most frequent is hepatopathy (elevated liver enzymes; >100 citations). Affection of the peripheral nerves manifests almost exclusively as neuropathy (Table 2). The most frequent ophthalmologic abnormalities include optic atrophy and pigmentary retinopathy (Table 3). Among the otologic abnormalities, hypoacusis is by far the most frequent. Renal insufficiency and anemia are the most frequent abnormalities among the nephrological and hematological abnormalities. Thus the combination of the key features ptosis, ophthalmoparesis, easy fatigability, epilepsy, cerebral atrophy, ataxia, Parkinson syndrome, dementia, diabetes, cardiomyopathy, hepatopathy, neuropathy, optic atrophy, retinopathy, and hypoacusis (all >100 citations) is highly suggestive of an MID. In addition to clinical features, abnormalities detectable on routine instrumental investigations were included. For example, myopathy may manifest not only with classical clinical manifestations but also with instrumental abnormalities, particularly hyper-CK-emia and abnormal cycle lactate stress test. More rarely than in muscular dystrophies, the EMG may be myogenic. Myopathy may also manifest exclusively with reduced tendon reflexes. Hyponatremia can be occasionally observed in MIDs without being attributed to drugs, diet, emesis, sweating, or renal insufficiency. In these cases, Addison’s disease or Fanconi syndrome (low molecular weight proteins, glucose, amino acid, uric acid, phosphate, and bicarbonate not reabsorbed in proximal tubules resulting in proteinuria, glucosuria, aminoaciduria, hypophosphatemia, and metabolic acidosis)22 should be considered. Renal tubular acidosis with or without Fanconi syndrome may be a rare manifestation of an MID.23,24 If the ANS is additionally affected in neuropathy, it may manifest as dry skin, hypohidrosis, or hyperhidrosis. In addition, there may be oversensitivity to light, sicca syndrome (xerostomia), decreased heart rate variability, orthostasis or syncope, gustatory sweating, obstipation, overactive bladder (detrusor overactivity), or impotence. Diseases of the arteries such as atherosclerosis, dissection, ectasia, aneurysm formation, or spontaneous rupture are not well appreciated as a manifestation of an MID.25–29 The number of patients with such vascular abnormalities is limited to a few cases (Table 2). Nevertheless, there is an increasing evidence that these abnormalities can be clearly related to MID in the few available reports. Although hematological disease is increasingly recognized as a manifestation of MIDs, it is still underdiagnosed and underreported. Bone marrow involvement includes anemia, thrombocytopenia, and leukopenia. Among the sepcific MIDs, such hematological abnormalities occur in Pearson syndrome, KSS, Barth syndrome, mitochondrial myopathy, lactic acidosis and sideroblastic anemia, X-linked sideroblastic anemia, Leigh syndrome, Leber’s hereditary optic neuropathy, MELAS, and thiamine-responsive megaloblastic anemia.30 However, hematological abnormalities occur more frequently in non-specific MIDs than in specific MIDs.30 Whether eosinophilia, as found in one of the patients of the present study, should be attributed to MIDs remains speculative and requires further investigations. Dermatological involvement is also hardly recognized as mitochondrial, but there is growing evidence that MIDs also manifest in the skin or its appendages.31 Dermatological involvement in MIDs includes psoriasis, vitiligo, baldness, alopecia, madarosis, hypertrichosis, skin rashes, seborrheic eczema, atopic dermatitis, or edema. Not all these aspects were found in the present study but reported in the literature (Table 2). Congenital heart disease as a manifestation of MIDs is also rare but has been described in single patients (Table 2).32 Diverticulosis is also hardly recognized as a manifestation of MIDs but is prevalent particular among nonspecific MIDs, without being frequently reported. Ischemic stroke should not be regarded as a primary manifestation of MIDs but rather as secondary in case classical risk factors for atherosclerosis, such as mitochondrial diabetes, hyperlipidemia, arterial hypertension, severe heart failure, and LVHT, are present. Altogether, only 71% of the 94 reported abnormalities described in the literature (Table 2) were also found in the present study. Abnormalities that have not been previously described in MID patients but have been found in the present investigation include liver cysts, RLS, eosinophilia, arachnoidal cysts, prostate hypertrophy, and endometriosis. Whether these abnormalities can truly be regarded as manifestations of the mitochondrial defect and whether valve abnormalities, pericarditis, and abnormal myocardial texture should be regarded as an MID manifestation remain speculative. It is also not established that nephrolithiasis is an authentic manifestation of MIDs. According to our own experience, however, nephrolithiasis particularly occurs as an initial manifestation at the onset of adult MIDs. Syncope is multi-causal but if due to a seizure or a cardiac arrhythmia an MID should be considered if no other explanations impose oneself. Syncope may be also due to arterial hypotension, which in turn could be a manifestation of adrenal insufficiency or bradyarrhythmia. Limitations of the study were that it was retrospective, thus not all patients went through the same clinical screening, that the records could not be completely pursued in each case, that the genetic defect was not identified in each case (biochemical defects could have been secondary), that the number of included patients was low, that no control group or disease control group (eg, autoimmune disorders and myotonic dystrophy) was investigated, that the score was not validated, that the score does not predict the severity of the disease, that the number of matching PubMed citations for each MID manifestation was only approximately determined, that the number of PubMed hits may not adequately reflect the frequency of abnormalities, and that not all organs potentially affected in MIDs were also investigated in each patient. A further limitation is that biochemical and genetic studies were carried out in only 2 patients. A single biochemical defect usually reflects a mutation in one of the genes encoding the subunits of the corresponding respiratory chain complex. Multiple biochemical defects usually reflect tRNA mutations or mtDNA depletion.

Conclusion

This study shows that adult MIDs manifest as MIMODS in the vast majority of the cases; that organs most frequently affected in MIMODS are the muscle, CNS, endocrine glands, and heart; and that an MIMODS score >10 suggests an MID and thus could be a helpful parameter to assess, by nonsophisticated, clinical means, whether an MID is present or not.
  100 in total

1.  Diagnostic challenges in movement disorders: Sensory Ataxia Neuropathy Dysarthria and Ophthalmoplegia (SANDO) syndrome.

Authors:  Alyson Lovan; Nikhil Balakrishnan
Journal:  BMJ Case Rep       Date:  2013-08-30

2.  Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation.

Authors:  Sarah Doss; Katja Lohmann; Philip Seibler; Björn Arns; Thomas Klopstock; Christine Zühlke; Karen Freimann; Susen Winkler; Thora Lohnau; Mario Drungowski; Peter Nürnberg; Karin Wiegers; Ebba Lohmann; Sadaf Naz; Meike Kasten; Georg Bohner; Alfredo Ramirez; Matthias Endres; Christine Klein
Journal:  J Neurol       Date:  2013-11-08       Impact factor: 4.849

3.  Dilation of the aortic root in mitochondrial disease patients.

Authors:  Nicola Brunetti-Pierri; Ricardo Pignatelli; Negin Fouladi; Jeffrey A Towbin; John W Belmont; William J Craigen; Lee-Jun Wong; John L Jefferies; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2011-02-18       Impact factor: 4.797

4.  Mitochondrial DNA deletion associated oxidative stress and severe male osteoporosis.

Authors:  S S Varanasi; R M Francis; C E Berger; S S Papiha; H K Datta
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

5.  Mitochondrial DNA deletion mutations in articular chondrocytes of cartilage affected by osteoarthritis.

Authors:  Hong-bin Lü; Yun Zhou; Jian-zhong Hu; Guang-hua Lei; Min Zhu; Kang-hua Li
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2006-10

6.  Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA MT-CO2 gene.

Authors:  Christoffer Rasmus Vissing; Morten Duno; Jess Have Olesen; Jabin Rafiq; Lotte Risom; Ernst Christensen; Flemming Wibrand; John Vissing
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

7.  Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G>A) in the mitochondrial encoded ATP6 gene.

Authors:  Lindsay C Burrage; Sha Tang; Jing Wang; Taraka R Donti; Magdalena Walkiewicz; J Michael Luchak; Li-Chieh Chen; Eric S Schmitt; Zhiyv Niu; Rodrigo Erana; Jill V Hunter; Brett H Graham; Lee-Jun Wong; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2014-06-30       Impact factor: 4.797

8.  Aortic rupture in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes.

Authors:  Stacey H K Tay; Douglas R Nordli; Eduardo Bonilla; Edward Null; Sara Monaco; Michio Hirano; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2006-02

9.  [Progressive external ophthalmoplegia and the Kearns-Sayre syndrome: a clinical and molecular study of 6 cases].

Authors:  A Barrientos; J Casademont; J M Grau; F Cardellach; J Montoya; X Estivill; A Urbano-Márquez; V Nunes
Journal:  Med Clin (Barc)       Date:  1995-07-01       Impact factor: 1.725

10.  Association of the mtDNA m.4171C>A/MT-ND1 mutation with both optic neuropathy and bilateral brainstem lesions.

Authors:  Chiara La Morgia; Leonardo Caporali; Francesca Gandini; Anna Olivieri; Francesco Toni; Stefania Nassetti; Daniela Brunetto; Carlotta Stipa; Cristina Scaduto; Antonia Parmeggiani; Caterina Tonon; Raffaele Lodi; Antonio Torroni; Valerio Carelli
Journal:  BMC Neurol       Date:  2014-05-28       Impact factor: 2.474

View more
  8 in total

1.  Polymegathism as a biomarker of mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-13       Impact factor: 3.117

Review 2.  The Novel Role of PGC1α in Bone Metabolism.

Authors:  Cinzia Buccoliero; Manuela Dicarlo; Patrizia Pignataro; Francesco Gaccione; Silvia Colucci; Graziana Colaianni; Maria Grano
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

3.  Early identification of LHON carriers may improve outcome.

Authors:  Josef Finsterer
Journal:  Rom J Ophthalmol       Date:  2019 Jan-Mar

4.  Malingering and Factitious Disorder (Münchausen-syndrome) can be Mitochondrial.

Authors:  Josef Finsterer; Lässer Stefan
Journal:  Indian J Psychol Med       Date:  2016 Jul-Aug

Review 5.  Biomarkers for Detecting Mitochondrial Disorders.

Authors:  Josef Finsterer; Sinda Zarrouk-Mahjoub
Journal:  J Clin Med       Date:  2018-01-30       Impact factor: 4.241

6.  Aortic root ectasia as a phenotypic feature of a mitochondrial disorder.

Authors:  Josef Finsterer
Journal:  Clin Case Rep       Date:  2018-06-17

7.  Liability of sepsis is hardly determined by the COXI variant m.6459T>C.

Authors:  Josef Finsterer
Journal:  J Cell Mol Med       Date:  2018-10-18       Impact factor: 5.310

8.  MELAS Missed for Years: Stroke-Like Lesions Are No Indication for Brain Biopsy.

Authors:  J Finsterer
Journal:  Case Rep Neurol Med       Date:  2019-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.